Search results
Is CRISPR Therapeutics a Millionaire Maker?
Motley Fool via Yahoo Finance· 5 days agoThe company also has other high-impact clinical programs in later stages of development which are intended to treat conditions like renal cell ...
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
Zacks via Yahoo Finance· 5 days agoPer BMY, this is the first phase III study of the subcutaneous formulation of nivolumab to evaluate...
Director Julie Smith Sells 27,280 Shares of Exelixis Inc (EXEL) By GuruFocus
Investing.com· 4 days agoFollowing this transaction, the insider now owns 5,445 shares of Exelixis Inc. Exelixis Inc is a...
ASCO Meeting News Research News and Press Releases
Newswise· 5 days agoNewswise - ASCO Meeting News: ASCO Meeting News Page 1
Rutgers Cancer Institute and RWJBarnabas Health Se | Newswise
Newswise· 5 days agoClinicians and scientists from Rutgers Cancer Institute and RWJBarnabas Health will lead sessions...
Get Ready for ASCO 2024 Annual Meeting | Newswise
Newswise· 6 days agoASCO, the largest event in cancer research, is approaching on May 31st. This year's meeting promises to be particularly groundbreaking, with new findings a
Tumor mutations may not predict response to immuno | Newswise
Newswise· 6 days agoMay 22, 2024 – The number of mutations in the DNA of cancerous tumors may not be an indicator of how...
Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based...
WTNH-TV New Haven· 4 days agoData will be showcased at the 2024 American Society of Clinical Oncology (ASCO) annual meeting....
Assetmark Inc. Boosts Stock Position in BeiGene, Ltd. (NASDAQ:BGNE)
ETF DAILY NEWS· 2 days agoAssetmark Inc. boosted its holdings in shares of BeiGene, Ltd. (NASDAQ:BGNE – Free Report) by 13.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange ...
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
Zacks· 6 days agoFree Report) announced that the FDA will now decide on the biologics license application (BLA) for the subcutaneous formulation of Opdivo (nivolumab) on Dec 29, 2024. The subcutaneous formulation ...